Biotech

All Articles

Actinogen's cortisol blocker falls short stage 2 anxiety study

.Actinogen Medical's cortisol blocker has missed out on the major endpoint of a stage 2 study in cli...

Bivictrix chooses going personal only method to take ADC right into medical clinic

.Antibody-drug conjugates (ADCs) have gone to the center of numerous a billion-dollar biobuck licens...

TPG tops up funds to $580M for assets throughout lifestyle sciences

.Resource manager TPG, which has actually assisted biotechs like Sionna Therapeutics and also Santa ...

Merck quits stage 3 TIGIT test in lung cancer for impossibility

.Merck &amp Co.'s TIGIT course has actually experienced another misfortune. Months after shuttering ...

After a difficult year, Exscientia folds up into Recursion

.After a year specified by pipe cuts, the variation of its chief executive officer as well as unempl...

Cullinan, after $25M bargain, hands back bispecific to Port

.Cullinan Rehab was thrilled enough along with Harbour BioMed's bispecific immune reactor that it ha...

A deeper check out Brutal Biotech's Ferocious 15

.In this particular week's episode of "The Leading Pipe," our company're diving in to Tough Biotech'...

Lilly faces stage 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's party celebrating the commendation o...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of notable management hirings, shootings as well...

Lykos will ask FDA to reconsider its choice observing turndown of MDMA treatment for post-traumatic stress disorder

.Adhering to an unsatisfactory revealing for Lykos Therapies' MDMA applicant for post-traumatic stre...